Evidence map›Paper›PMID 22574985›Full record

ReviewCurrent pharmaceutical design2012

CD36 as a therapeutic target for endothelial dysfunction in stroke.

Sunghee Cho

Open access · greenAbstract readReview
In one paragraph

Review in Current pharmaceutical design, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed
2.0field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 51 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Role of CD36 in central nervous system diseases.Neural regeneration research · 2024
    Review
  6. Article
  7. NWorld journal of diabetes · 2023
    Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Review
  15. Review
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Sunghee ChoDepartment of Neurology/ Neuroscience, Weill Cornell Medical College at Burke Medical Research Institute, 785 Mamaroneck Ave., White Plains, New York 10605, USA. suc2002@med.cornell.edu
Cornell University · US

Funding

The role of CD36 in ischemic inflammation and injuryR01HL082511 · NHLBI · WINIFRED MASTERSON BURKE MED RES INST · PI CHO, SUNGHEE · 2006 to 2014
$4.4M
NHLBI NIH HHS HL82511NHLBI NIH HHS HL82511-04S1NHLBI NIH HHS R01 HL082511
6 · The paper itself

Abstract

Stroke pathology involves multifactorial pro-death responses, including inflammation, oxidative stress, vascular dysfunction, and activation of necrotic and apoptotic pathways. The interruption of a single specific pathway in defined stroke model systems has not been sufficient to address the multifactorial nature of stroke-induced injuries in the human population. CD36 is a class B scavenger receptor that functions in regulating normal physiological and pathological functions. CD36 pathways are activated by several distinct ligands. Convergence of these pathways results in inflammatory responses and endothelial dysfunction, which may be an underlying cause of cardio- and cerebrovascular diseases. The current review describes receptor CD36-ligand interactions relevant to endothelial function and discusses how targeting CD36 may have therapeutic utility in stroke.

Indexed as

CD36 AntigensEndothelium, VascularHumansLigandsNeovascularization, PathologicStrokeCD36 AntigensLigands

Identifiers

PMID22574985
PMCPMC3411860
OpenAlexW1996490160

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.